NXTC · XBRL financial data

NextCure financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (NXTC's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	11,010	11,827*	11,398	12,418	8,770	8,902*	7,896	24,091	6,136	6,800*	6,834	7,425
General and administrative	4,608	3,963*	4,364	4,076	3,725	3,553*	3,726	3,201	2,809	2,957*	3,271	2,592
Total operating expenses	15,618	15,790*	18,304	16,494	12,495	12,455*	11,622	27,292	8,945	9,757*	10,105	15,094
Operating income (loss)	(15,618)	(15,790)*	(18,304)	(16,494)	(12,495)	(12,455)*	(11,622)	(27,292)	(8,945)	(9,757)*	(10,105)	(15,094)
Other income (expense)	1,317	1,323*	1,197	1,090	955	852*	646	484	321	321*	309	202
Income tax expense (benefit)	0	—	0	0	0	—	0	0	0	0*	0	0
Net income (loss)	(14,301)	(14,467)*	(17,107)	(15,404)	(11,540)	(11,603)*	(10,976)	(26,808)	(8,624)	(9,436)*	(9,796)	(14,892)
Earnings per share, basic‡ USD per share	(6.38)	(6.50)*	(7.63)	(6.88)	(5.13)	(5.13)*	(4.88)	(141.13)	(3.22)	—	(1.87)	(2.80)
Earnings per share, diluted‡ USD per share	(6.38)	(6.50)*	(7.63)	(6.88)	(5.13)	(5.13)*	(4.88)	(141.13)	(3.22)	—	(1.87)	(2.80)
Weighted average shares, basic‡ thousands of shares	2,227	2,232*	2,232	2,238	2,238	2,241*	2,241	190	2,676	—	5,239	5,310
Weighted average shares, diluted‡ thousands of shares	2,227	2,232*	2,232	2,238	2,238	2,241*	2,241	190	2,676	—	5,239	5,310

‡ Per-share figures and share counts are adjusted for the 1-for-12.5 stock split (December 2025); filings made before it reported them unadjusted.

Balance sheet

CSV

Fiscal quarters (NXTC's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	19,519	13,082	18,358	20,848	27,702	27,727	21,827	4,892	7,324	25,982	15,167	15,260
Prepaid and other current assets	4,478	4,426	6,551	4,019	3,385	3,186	3,037	4,707	3,530	1,929	1,998	2,167
Total current assets	122,684	112,725	102,552	90,455	78,693	71,807	58,897	40,015	32,640	43,747	31,741	22,255
Property and equipment, net	9,844	9,033	7,097	6,699	6,167	5,458	4,804	4,171	3,638	3,273	2,990	283
Right-of-use asset	4,557	4,398	3,632	3,561	3,415	3,263	3,108	2,948	2,785	2,617	2,399	—
Total assets	139,939	128,038	115,159	102,589	90,345	80,860	67,137	47,689	39,613	50,183	37,977	22,620
Accounts payable	2,602	2,330	4,491	5,075	3,613	5,353	2,736	2,544	2,391	2,011	3,070	2,578
Total current liabilities	6,552	6,883	9,583	10,833	8,672	9,574	5,740	10,781	10,995	10,566	6,891	6,413
Lease liability, non-current	6,120	5,949	5,773	5,590	5,388	5,153	4,913	4,666	4,411	4,148	3,879	3,603
Total liabilities	13,487	13,617	16,111	17,148	14,753	15,388	11,282	16,043	15,967	15,240	11,261	10,471
Accumulated deficit	(310,015)	(324,482)	(341,589)	(356,993)	(368,533)	(380,136)	(391,112)	(417,920)	(426,544)	(435,980)	(445,776)	(460,668)
Total stockholders' equity	126,452	114,421	99,048	85,441	75,592	65,472	55,855	29,646	23,646	34,943	26,716	12,149
Total liabilities and equity	139,939	128,038	115,159	102,589	90,345	80,860	67,137	47,689	39,613	50,183	37,977	22,620
Common shares outstanding (cover page)‡ thousands of shares	2,232	2,232	2,238	2,238	2,241	2,241	2,244	214	2,680	3,560	3,612	4,577

‡ Per-share figures and share counts are adjusted for the 1-for-12.5 stock split (December 2025); filings made before it reported them unadjusted.

Cash flows

CSV

Fiscal quarters (NXTC's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(14,301)	(14,467)*	(17,107)	(15,404)	(11,540)	(11,603)*	(10,976)	(26,808)	(8,624)	(9,436)*	(9,796)	(14,892)
Stock-based compensation	2,001*	1,984*	1,693	1,594*	1,529*	1,519*	1,363	588*	600*	435*	344	304*
Depreciation and amortization	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net cash from operating activities	(12,778)*	(10,670)*	(12,606)	(9,776)*	(11,454)*	(6,969)*	(12,994)	(22,713)*	(6,268)*	(7,638)*	(13,363)	(9,715)*
Purchases of property and equipment	279*	13*	37	301*	170*	(34)*	—	—	—	—	—	—
Net cash from investing activities	10,278*	4,162*	17,881	12,160*	18,307*	6,958*	7,094	3,759*	8,700*	6,003*	1,300	9,786*
Proceeds from issuing common stock	—	year only	—	—	0*	0*	—	—	—	—	1,234	0*
Net cash from financing activities	0*	71*	1	106*	1*	36*	—	—	0*	20,293*	1,248	22*
Net change in cash	(2,500)*	(6,437)*	5,276	2,490*	6,854*	25*	(5,900)	(16,935)*	2,432*	18,658*	(10,815)	93*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
NextCure	15,260	not reported	(9,715)*	4.6M	1.6 quarters	Q2 FY26 10-QJun 30, 2026
Cellectar Biosciences	33,994	not reported	(6,010)*	9.5M	5.7 quarters	Q2 FY26 10-QJun 30, 2026
Synergy CHC	292	5,493	(2,045)	14.9M	0.1 quarters	Q1 FY26 10-QMar 31, 2026
Cypherpunk Technologies	7,624	not reported	(2,692)*	107.8M	2.8 quarters	Q2 FY26 10-QJun 30, 2026
Earth Science Tech	631	9,026	707	287.6M	—	Q1 FY27 10-QJun 30, 2026
Cocrystal Pharma	2,169	105	(2,516)*	19.3M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
GeoVax Labs	3,143	not reported	(3,658)*	7.4M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Citius Pharmaceuticals	17,008	1,494	(8,678)*	27.5M	2.0 quarters	Q3 FY26 10-QJun 30, 2026
Edesa Biotech	10,300	not reported	(3,083)*	9.6M	3.3 quarters	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.